NAPSR News: Novartis grabs early FDA approval of lung cancer drug Zykadia
Novartis has won early FDA approval for their new drug; Zykadia.
The agency approved the drug for ALK-positive non-small cell lung cancer among patients already treated with Xalkori (crizotinib)
The FDA's approval of Zykadia marks a new chapter in cancer drug development.
Investigators for the pharma giant recently reported that in a group of 114 ALK-positive lung cancer patients taking a daily dose ranging up from 400 mg, investigators tracked a 58% overall response that included complete and partial responses and a median progression-
An early approval like this could also encourage other developers to shoot for accelerated approval in cancer. Pfizer, which is now focused on a megamerger with AstraZeneca, has been studying its chances with the breast cancer drug palbociclib. And Novartis has also been hinting recently that it may take the plunge on Phase II data for LDE225, an oral therapy for basal cell carcinoma.
Novartis didn't miss the chance of celebrating its effectiveness in the cancer drug field, an arena that is slated to soon swell as it swaps out its vaccines business for GlaxoSmithKline's oncology drugs--along with rights to its AKT inhibitor afuresertib--
"The approval of Zykadia less than three and a half years after the first patient entered our clinical trial exemplifies what is possible with a highly focused approach to drug development and strong collaboration,"
"Today's approval illustrates how a greater understanding of the underlying molecular pathways of a disease can lead to the development of specific therapies aimed at these pathways," said Pazdur in a statement. "It also demonstrates the FDA's commitment to working cooperatively with companies to expedite a drug's development, review and approval, reflecting the promise of the breakthrough therapy designation program."
NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!
With such industry leaders posting gains in profitability, they will need both certified and qualified individuals to sell their product. When industry leaders look for new candidates for entry level positions, they look toward individuals that are industry trained. Reason being that they are looking for people that have the background to sell their product both proficiently and efficiantly.
CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. The CNPR® represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.
Individuals that are interested in becoming a Certified National Pharmaceutical Representative(